These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36920465)

  • 1. Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study.
    Zhuparris A; Maleki G; Koopmans I; Doll RJ; Voet N; Kraaij W; Cohen A; van Brummelen E; De Maeyer JH; Groeneveld GJ
    JMIR Form Res; 2023 Mar; 7():e41178. PubMed ID: 36920465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective Monitoring of Facioscapulohumeral Dystrophy During Clinical Trials Using a Smartphone App and Wearables: Observational Study.
    Maleki G; Zhuparris A; Koopmans I; Doll RJ; Voet N; Cohen A; van Brummelen E; Groeneveld GJ; De Maeyer J
    JMIR Form Res; 2022 Sep; 6(9):e31775. PubMed ID: 36098990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
    LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
    BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.
    Mellion ML; Widholm P; Karlsson M; Ahlgren A; Tawil R; Wagner KR; Statland JM; Wang L; Shieh PB; van Engelen BGM; Kools J; Ronco L; Odueyungbo A; Jiang J; Han JJ; Hatch M; Towles J; Leinhard OD; Cadavid D
    Neurology; 2022 Aug; 99(9):e877-e889. PubMed ID: 35750498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
    Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE
    BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
    Katz NK; Hogan J; Delbango R; Cernik C; Tawil R; Statland JM
    Brain; 2021 Dec; 144(11):3451-3460. PubMed ID: 34542603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.
    Gros M; Nunes AM; Daoudlarian D; Pini J; Martinuzzi E; Barbosa S; Ramirez M; Puma A; Villa L; Cavalli M; Grecu N; Garcia J; Siciliano G; Solé G; Juntas-Morales R; Jones PL; Jones T; Glaichenhaus N; Sacconi S
    J Neuromuscul Dis; 2022; 9(1):83-93. PubMed ID: 34459413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy.
    Gidaro T; Gasnier E; Annoussamy M; Vissing J; Attarian S; Mozaffar T; Iyadurai S; Wagner KR; Vissière D; Walker G; Shukla SS; Servais L
    Muscle Nerve; 2022 Feb; 65(2):237-242. PubMed ID: 34687225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.
    Eichinger K; Heatwole C; Heininger S; Stinson N; Matichak Stock C; Grosmann C; Wagner KR; Tawil R; Statland JM;
    Muscle Nerve; 2017 Mar; 55(3):333-337. PubMed ID: 27421252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An instrumented timed up and go in facioscapulohumeral muscular dystrophy.
    Huisinga J; Bruetsch A; Mccalley A; Currence M; Herbelin L; Jawdat O; Pasnoor M; Dimachkie M; Barohn R; Statland J
    Muscle Nerve; 2018 Mar; 57(3):503-506. PubMed ID: 28877559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging Mobile Phone Sensors, Machine Learning, and Explainable Artificial Intelligence to Predict Imminent Same-Day Binge-drinking Events to Support Just-in-time Adaptive Interventions: Algorithm Development and Validation Study.
    Bae SW; Suffoletto B; Zhang T; Chung T; Ozolcer M; Islam MR; Dey AK
    JMIR Form Res; 2023 May; 7():e39862. PubMed ID: 36809294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.
    Carraro E; Greco LC; Lizio A; Beretta M; Pozzi S; Casiraghi J; Becchiati S; Beshiri F; Frisoni MC; Iossa F; Heatwole C; Sansone V
    Disabil Rehabil; 2024 May; 46(10):2130-2137. PubMed ID: 37194629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updating the Clinical Picture of Facioscapulohumeral Muscular Dystrophy: Ramifications for Drug Development With Potential Solutions.
    Huml RA; Uspenskaya-Cadoz O; Dawson J; Slifer Z
    Ther Innov Regul Sci; 2020 Jan; 54(1):144-150. PubMed ID: 32008231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.
    Goselink RJM; Mul K; van Kernebeek CR; Lemmers RJLF; van der Maarel SM; Schreuder THA; Erasmus CE; Padberg GW; Statland JM; Voermans NC; van Engelen BGM
    Neurology; 2019 Jan; 92(4):e378-e385. PubMed ID: 30568007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the patient-reported "Facial Function Scale" for facioscapulohumeral muscular dystrophy.
    Mul K; Wijayanto F; Loonen TGJ; Groot P; Vincenten SCC; Knuijt S; Groothuis JT; Maal TJJ; Heskes T; Voermans NC; Engelen BGMV
    Disabil Rehabil; 2023 May; 45(9):1530-1535. PubMed ID: 35575310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facioscapulohumeral muscular dystrophy functional composite outcome measure.
    Eichinger K; Heatwole C; Iyadurai S; King W; Baker L; Heininger S; Bartlett A; Dilek N; Martens WB; Mcdermott M; Kissel JT; Tawil R; Statland JM
    Muscle Nerve; 2018 Jan; ():. PubMed ID: 29381807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.